ValiRx PLC Appointment of Broker (6656J)
25 Agosto 2021 - 1:01AM
UK Regulatory
TIDMVAL
RNS Number : 6656J
ValiRx PLC
25 August 2021
25 August 20 21
ValiRx Plc
( " ValiRx" or the " Company ")
Appointment of Broker
ValiRx Plc (AIM: VAL), has appointed Cenkos Securities plc
("Cenkos") as its sole broker with immediate effect.
In connection with the appointment of Cenkos, the Company has
granted Cenkos with a warrant over 3,902,949 ordinary shares in the
Company exercisable at price of 22p, being the closing mid-price on
24 August 2021 ("Warrants"). The Warrants are exercisable in whole
or in part for the period commencing 12 months after the
commencement of their engagement and ending 60 months after their
engagement.
Dr Kevin Cox, Chairman commented: "We are very much looking
forward to working closely with the Cenkos growth companies team to
help deliver and further develop the strategy we have been building
over the last year. After a period of consolidation and stability,
this is a natural evolution in our growth plans."
ValiRx plc Tel: +44 (0) 2476 796496
www.valirx.com
Suzanne Dilly, CEO Suzanne.Dilly@valirx.com
Cairn Financial Advisers LLP (Nominated Tel: +44 (0) 20 7213
Adviser) 088
Liam Murray / Jo Turner / Ludovico Lazzaretti
Cenkos Securities Plc (Broker) Tel: +44 (0)20 7397
Russell Kerr/Michael Johnson (Sales) 8900
Callum Davidson/Giles Balleny (Corporate
finance)
About ValiRx plc
ValiRx accelerates the development of treatments in oncology and
women's health to improve patient lives. We provide the scientific,
financial and commercial framework towards enabling rapid
translation of innovative science into clinical development.
With our extensive and proven experience in research and drug
development, we select and incubate promising novel drug candidates
and guide them through an optimised process of development, from
pre-clinical studies to clinic and investor-ready assets.
Integrating science and business
We connect diverse disciplines across scientific, technical and
commercial domains, with the aim of achieving a more streamlined,
less costly, drug development process. We work closely with our
selected collaborators and leverage the combined expertise required
for science to advance.
Lead candidates from our portfolio are out-licensed or partnered
with investors through ValiRx subsidiary
companies for further clinical development and commercialisation. https://www.valirx.com/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
APPDKQBQOBKDFFB
(END) Dow Jones Newswires
August 25, 2021 02:01 ET (06:01 GMT)
Valirx (LSE:VAL)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Valirx (LSE:VAL)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024